Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Harrow Now Offering Fortisite Formulations for In-Office Use
Harrow announced the availability of Fortisite (compounded Tobramycin 1.5% + Vancomycin 5%) for in-office use from its FDA-registered and FDA-inspected ImprimisRx 503B outsourcing facility. Fortisite formulations are high-concentration, refrigeration-stable, fortified antibiotic formulations in solution that are patent-pending. According to Harrow,…
RCA Acquires Retina Group of New England
Retina Consultants of America (RCA) announced it has added Retina Group of New England (RGNE) into its network of physicians. With this expansion, RCA will enter its 30th partnership and open operations in Connecticut, expanding its presence to 20 states…
FDA Greenlights Genentech’s Vabysmo | OBN
The FDA has approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), marking the first bispecific antibody approved for the eye. Vabysmo is also the first and only FDA-approved injectable eye…
Amgen to Buy Horizon Therapeutics
Amgen announced it is acquiring rare disease drug company Horizon Therapeutics, maker of eye disease drugs Tepezza and Uplizna, in a deal valued at $27.8 billion. The company will pay $116.50 in cash per share, a premium of 19.7% to…
Turkey, Lets In The SIFI 6th Biggest Pharma. Company In Europe
The Granting of Marketing Authorizations in Turkey – The Turkish Medicines and Medical Devices Agency (TMMDA) has approved the transfer of marketing authorizations for “SIFI”, a leading ophthalmic company, headquartered in Italy, focusing on eye care since 1935. Leading ophthalmic products, including NETILDEX®, NETIRA® and EYESTIL® will…